Harbour BioMed, AstraZeneca sign license deal for bispecific antibody
Harbour BioMed (HBM) and AstraZeneca have entered into a global out-license agreement for CLDN18.2xCD3 bispecific antibody HBM7022.
Based Immune Cell Engagers News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Based Immune Cell Engagers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Based Immune Cell Engagers Today - Breaking & Trending Today
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
/PRNewswire/ -- Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and...
Source: prnewswire.com
Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting
/PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel...
Source: prnewswire.com